SCA
EW icon

SAC Capital Advisors’s Edwards Lifesciences EW Stock Holding History

SAC Capital Advisors’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-900,000
Closed -$11.1M – 343
2014
Q1 		$11.1M Buy
+900,000
New +$10.4M 0.06% 380
2013
Q4 		– Sell
-1,500,000
Closed -$17.4M – 1831
2013
Q3 		$17.4M Buy
+1,500,000
New +$17.5M 0.09% 258

Other funds holding EW

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
FC
Fairpointe Capital Chicago, Illinois $66.3M AUM 101.32% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

SAC Capital Advisors's EW Position: Q2 2014 in Review

SAC Capital Advisors sold out of Edwards Lifesciences (EW) in Q2 2014, closing a stake of 79,668 shares — an estimated $985K sold.

SAC Capital Advisors first reported a position in EW in Q2 2013 and held it in 4 quarters. The position peaked at $35.3M in Q3 2013. 428 funds tracked by Wall St. Rank hold EW as of Q2 2014.

  • SAC Capital Advisors reported no remaining Edwards Lifesciences position as of Q2 2014 after selling out during the quarter.
  • SAC Capital Advisors sold 79,668 Edwards Lifesciences shares in Q2 2014, an estimated $985K.
  • SAC Capital Advisors first reported a position in Edwards Lifesciences in Q2 2013 and held it in 4 quarters.
  • SAC Capital Advisors's Edwards Lifesciences position peaked at $35.3M in Q3 2013.
  • 428 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2014.

Based on SAC Capital Advisors's 13F filing for Q2 2014.